Patients receiving an immune checkpoint inhibitor for a neoplasm face an increased risk for rheumatoid arthritis, an observational study found.

US FDA approves expanded label for Astellas’ Izervay for the treatment of geographic atrophy: Tokyo Friday, February 14, 2025, 09:00 Hrs [IST] Astellas Pharma Inc., a global lif ...

More than 50% of patients with systemic lupus erythematosus (SLE) develop lupus nephritis (LN) during the disease, which may ...

SE (NASDAQ:ARGX – Get Free Report) has earned an average rating of “Moderate Buy” from the twenty-two ratings firms that are presently covering the firm, Marketbeat.com reports. One investment analyst ...

Choreo LLC lifted its holdings in argenx SE (NASDAQ:ARGX – Free Report) by 4.4% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange ...

Children diagnosed with interstitial lung disease often survive into adulthood, when they are likely to need care for related impairments.

This feature is a deep dive into the challenges of defining and treating Difficult-to-Treat Rheumatoid Arthritis (D2T-RA).